Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2010
  • Online publication date: May 2010

Chapter 11 - Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome

Summary

In the United States, second-generation antipsychotics have become the most widely used drugs in the treatment of schizophrenia, with total annual costs of over $12 billion. While the main CATIE analysis showed that patients stayed on olanzapine longer than two other second-generation antipsychotics, none of four second-generation antipsychotics, showed any advantage over the first-generation antipsychotic perphenazine on measures of symptoms. The cost-benefit analysis presented here, which combines cost and benefit data in a single analysis, found perphenazine to be superior to each of the four second-generation antipsychotics with which it was compared. While cost-effectiveness analysis evaluates the health benefits per additional dollar expended using the measures of quality of life, cost-benefit analysis attempts to put monetary value on the health benefits of treatment and thus monetizes all outcomes. Antipsychotic medication costs were based on wholesale prices for the specific capsule strengths used in CATIE, adjusted downward for discounts and rebates.

References

1. BlanchardJJ, BrownSA, HoranWP and SherwoodAR.Substance use disorders in schizophrenia: Review, integration, and a proposed model. Clinical Psychology Review 2000;20:207–34.
2. Cantor-GraaeE, NordstromLG and McNeilTF.Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophrenia Research 2001;48:69–82.
3. DixonL.Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophrenia Research 1999;35:S93–S100.
4. GoswamiS, MattooSJ, BasuD and SinghG.Substance-abusing schizophrenics: Do they self-medicate?The American Journal on Addictions 2004;13:139–50.
5. KavanaghDJ, McGrathJ, SaundersJB, DoreG and ClarkD.Substance misuse in patients with schizophrenia: Epidemiology and management. Drugs 2002;62:743–55.
6. KesslerRC, CrumRM, WarnerLA, NelsonCB, SchulenbergJ and AnthonyJC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry 1997;54:313–21.
7. McCreadieRG. Use of drugs, alcohol and tobacco by people with schizophrenia: Case-control study. British Journal of Psychiatry 2002;181:321–5.
8. MueserKT, DrakeRE and WallaceMA.Dual diagnosis: A review of etiological theories. Addictive Behaviors 1998;23:717–34.
9. RegierDA, FarmerME, RaeDS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association 1990;264:2511–8.
10. SalyersMP and MueserKT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophrenia Research 2001;48:109–23.
11. HaywoodTW, KravitaHM, GrossmanLS, CavanaughJL Jr, DavisJM and LewisDA. Predicting the “revolving door” phenomenon among patient with schizophrenic, schizoaffective, and affective disorders. American Journal of Psychiatry 1995;151:856–61.
12. SwartzMS, SwansonJW, HidayVA, BorumR, WagnerHR and BurnsBJ.Violence and severe mental illness: The effects of substance abuse and nonadherence to medication. American Journal of Psychiatry 1998;155:226–31.
13. SwoffordCD, KasckowJW, Scheller-GilkeyG and InderbitzinLB.Substance use: A powerful predictor of relapse in schizophrenia. Schizophrenia Research 1996;20:145–51.
14. SwansonJ, EstroffS, SwartzM, et al. Violence and severe mental disorder in clinical and community populations: The effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry 1997;60:1–22.
15. GoodmanLA, SalyersMP, MueserKT, et al. Recent victimization in women and men with severe mental illness: Prevalence and correlates. Journal of Traumatic Stress 2001;14:615–32.
16. RosenbergSD, GoodmanLA, OsherFC, et al. Prevalence of HIV, Hepatitis B and Hepatitis C in people with severe mental illness. American Journal of Public Health 2001;91:31–7.
17. AbramK and TeplinL.Co-occurring disorders among mentally ill jail detainees: Implications for public policy. The American Psychologist 1991;46:1036–44.
18. SwartzMS, SwansonJW and HannonMJ. Detection of illicit substance use in persons with schizophrenia. Psychiatric Services 2003;54:891–5.
19. StroupTS, McEvoyJP, SwartzMS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
20. SwartzMS, WagnerHR, SwansonJW, et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease 2006;194:164–72.
21. SwartzMS, WagnerHR, SwansonJW, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services 2006;57:1110–6.
22. SwartzMS, WagnerHR, SwansonJW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. Schizophrenia Research 2008;100:39–52.
23. FirstMB, SpitzerRL, GibbonM, et al. Structured Clinical Interview for Axes I and II DSM-IV Disorders-Patient Edition (SCID-I/P). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
24. DrakeR, OsherFC, NoordsyDL, HurlbutSC, TeagueGB and BeaudettMS. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 1990;16:57–67.
25. AddingtonD, AddingtonJ and SchisselB. A depression rating scale for schizophrenics. Schizophrenia Research 1990;3:247–51.
26. KaySR, FiszbeinA and Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
27. HeinrichsDW, HanlonTE and CarpenterWT Jr.The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388–98.
28. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Survey on Drug Use and Health. Washington, DC: HHS; 2006.
29. LiebermanJA, StroupTS, McEvoyJP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.